Centroblastic Diffuse Large B Cell Lymphoma Displays Distinct Expression Pattern and Prognostic Role of Apoptosis Resistance Related Proteins

REFERENCES

• Ng AK. Diffuse large B-cell lymphoma. Semin Radiat Oncol 2007;17:169–175.
   PubMed Web of Science ®Google Scholar
• Baars JW, de Jong D, Willemse EM, Gras L, Dalesio O, v Heerde P, Huygens PC, vd Lelie H, Kr vd Borne AE. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification. Br J Cancer 1999;79:1770–1776.
   PubMed Web of Science ®Google Scholar
• Diebold J, Anderson JR, Armitage JO, Connors JM, Maclennan KA, Muller-Hermelink HK, Nathwani BN, Ullrich F, Weisenburger DD. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 2002;43:97–104.
   PubMed Web of Science ®Google Scholar
• Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, Thiel E, Wilmanns W, Aydemir U, Bierwolf S, Griesser H, Tiemann M, Lennert K. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997;89:2291–2297.
   PubMed Web of Science ®Google Scholar
• Guzman-Rojas L, Sims-Mourtada JC, Rangel R, Martinez-Valdez H. Life and death within germinal centres: a double-edged sword. Immunology 2002;107:167–175.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22–33.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10:1419–1432.
   PubMed Web of Science ®Google Scholar
• de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003;43:509–528.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B, Zinzani PL. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002;41:482–509.
   PubMed Web of Science ®Google Scholar
• Salar A, Fernandez de Sevilla A, Romagosa V, Domingo-Claros A, Gonzalez-Barca E, Pera J, Climent J, Granena A. Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management? Eur J Haematol 1998;60:202–208.
   PubMed Web of Science ®Google Scholar
• Camara DA, Stefanoff CG, Pires AR, Soares F, Biasoli I, Zalcberg I, Spector N, Lopes VS, Morais JC. Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile. Leuk Lymphoma 2007;48:892–896.
   PubMed Web of Science ®Google Scholar
• Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, Stein H, Hansmann ML, Ott G, Rosenwald A, Müller-Hermelink HK, Barth TF, Möller P, Cogliatti SB, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller AC. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. Haematologica 2009;94:1569–1580.
   PubMed Web of Science ®Google Scholar
• Akyurek N, Ren Y, Rassidakis GZ, Schlette EJ, Medeiros LJ. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006;107:1844–1851.
   PubMed Web of Science ®Google Scholar
• Bai M, Skyrlas A, Agnantis NJ, Kamina S, Papoudou-Bai A, Kitsoulis P, Kanavaros P. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res 2005;25:347–362.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004;5:341–353.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004;18:616–623.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2008.
   Google Scholar
• Faccion RS, Ferreira RM, Grabois MF, Fonseca TC, de Oliveira JA, Maia RC. Lack of prognostic significance of survivin in pediatric medulloblastoma. Pathol Oncol Res 2011;17:899–908.
   PubMed Web of Science ®Google Scholar
• Phillips K, Luisi B. The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol 2000;302:1023–1039.
   PubMed Web of Science ®Google Scholar
• Meulmeester E, Jochemsen AG. p53: a guide to apoptosis. Curr Cancer Drug Targets 2008;8:87–97.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275–283.
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402–412.
   PubMed Web of Science ®Google Scholar
• Tun C, Guo W, Nguyen H, Yun B, Libby RT, Morrison RS, Garden GA. Activation of the extrinsic caspase pathway in cultured cortical neurons requires p53-mediated down-regulation of the X-linked inhibitor of apoptosis protein to induce apoptosis. J Neurochem 2007;102:1206–1219.
   PubMed Web of Science ®Google Scholar
• Plesnila N, von Baumgarten L, Retiounskaia M, Engel D, Ardeshiri A, Zimmermann R, Hoffmann F, Landshamer S, Wagner E, Culmsee C. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. Cell Death Differ 2007;14:1529–1541.
   PubMed Web of Science ®Google Scholar
• Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613–2622.
   PubMed Web of Science ®Google Scholar
• Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004;23:8146–8153.
   PubMed Web of Science ®Google Scholar
• Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007;6:1006–1010.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–1715.
   PubMed Web of Science ®Google Scholar
• Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513–522.
   PubMed Web of Science ®Google Scholar
• Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000;257:231–237.
   PubMed Web of Science ®Google Scholar
• Stein H, Hummel M. Histopathology in the light of molecular profiling. Ann Oncol 2006;17(Suppl 4):iv5–iv7.
   PubMedGoogle Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 60:393–408.
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Front-line management of diffuse large B cell lymphoma. Curr Opin Oncol 2010;22:642–645.
   PubMed Web of Science ®Google Scholar
• Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol 92:231–237.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, Richter LC, Miller TP. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157–1160.
   PubMed Web of Science ®Google Scholar
• Piris MA, Villuendas R, Martinez JC, Sanchez-Beato M, Orradre JL, Mateo MS, Martinez P. p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma 1995;17:35–42.
   PubMed Web of Science ®Google Scholar
• Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JH, de Jong D, Kluin PM. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131–2138.
   PubMed Web of Science ®Google Scholar
• Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, Kluin PM. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152–3162.
   PubMed Web of Science ®Google Scholar
• Maartense E, Kramer MH, le Cessie S, Kluin-Nelemans JC, Kluin PM, Snijder S, Noordijk EM. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry. Leuk Lymphoma 2004;45:101–107.
   PubMed Web of Science ®Google Scholar
• Monni O, Franssila K, Joensuu H, Knuutila S. BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 1999;34:45–52.
   PubMed Web of Science ®Google Scholar
• Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001;18:15–22.
   PubMed Web of Science ®Google Scholar
• Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park T, Shin DG, Sohn KR, Lee KB. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 2003;73:101–107.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma–a Nordic Lymphoma Group study. Ann Hematol 2004;83:414–419.
   PubMed Web of Science ®Google Scholar
• Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol 2008;81:289–297.
   PubMed Web of Science ®Google Scholar
• Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088–3098.
   PubMed Web of Science ®Google Scholar
• Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921–1925.
   PubMed Web of Science ®Google Scholar
• de Leval L, Hasserjian RP. Diffuse large B-cell lymphomas and burkitt lymphoma. Hematol Oncol Clin North Am 2009;23:791–827.
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495–516.
   PubMed Web of Science ®Google Scholar
• Ameisen JC. On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ 2002;9:367–393.
   PubMed Web of Science ®Google Scholar
• Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003;4:410–415.
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005;84:627–639.
   PubMed Web of Science ®Google Scholar
• Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083–1093.
   PubMed Web of Science ®Google Scholar
• Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol 2007;17:286–291.
   PubMed Web of Science ®Google Scholar
• Liu B, Chen Y, St Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 2008;44:1529–1535.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13–20.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867–873.
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311–322.
   PubMed Web of Science ®Google Scholar
• Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, Jocham D, Sczakiel G, Gerdes J, Bohle A. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer 2003;105:710–716.
   PubMed Web of Science ®Google Scholar
• Wang R, Luo D, Ma X, Yang W, Chen R, Liu Y, Meng L, Zhou J, Xu G, Lu YP, Wang S, Ma D. Antisense Ki-67 cDNA transfection reverses the tumorigenicity and induces apoptosis in human breast cancer cells. Cancer Invest 2008;26:830–835.
   PubMed Web of Science ®Google Scholar
• Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989;86:8763–8767.
   PubMed Web of Science ®Google Scholar
• Datta R, Oki E, Endo K, Biedermann V, Ren J, Kufe D. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem 2000;275:31733–31738.
   PubMed Web of Science ®Google Scholar
• Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 2002;180:91–101.
   PubMed Web of Science ®Google Scholar
• Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, Mitrou PS, Weidmann E, Chow KU. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma 2004;45:1429–1436.
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360–372.
   PubMed Web of Science ®Google Scholar
• Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol 2007;608:23–30.
   PubMed Web of Science ®Google Scholar
• Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007;28:1133–1139.
   PubMed Web of Science ®Google Scholar
• Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008;12:463–476.
   PubMed Web of Science ®Google Scholar
• Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken JH, Jiwa NM, Jansen PM, Kluin-Nelemans HC, Ossenkoppele GJ, Gundy C, Meijer CJLM, Oudejans JJ. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916–2923.
   PubMed Web of Science ®Google Scholar
• Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006;37:78–86.
   PubMed Web of Science ®Google Scholar
• Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell 2008;30:123–135.
   PubMed Web of Science ®Google Scholar
• LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008;27:6252–6275.
   PubMed Web of Science ®Google Scholar
• Russell JC, Whiting H, Szuflita N, Hossain MA. Nuclear translocation of X-linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia in neonatal brain. J Neurochem 2008;106:1357–1370.
   PubMed Web of Science ®Google Scholar
• Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997;90:1168–1174.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Evans PA, O'Connor SJ, Kendall SJ, Owen RG, Haynes AP, Morgan GJ, Jack AS. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003;9:2133–2139.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998;273:11177–11182.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–921.
   PubMed Web of Science ®Google Scholar
• Quillard T, Devalliere J, Chatelais M, Coulon F, Seveno C, Romagnoli M, Barille Nion S, Charreau B. Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PLoS One 2009;4:e8244.
   PubMed Web of Science ®Google Scholar
• Riley A, Jordan LE, Holcik M. Distinct 5’ UTRs regulate XIAP expression under normal growth conditions and during cellular stress. Nucleic Acids Res 2010;38:4665–4674.
   PubMed Web of Science ®Google Scholar
• Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol 2010;222:180–190.
   PubMed Web of Science ®Google Scholar
• Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011;35:787–792.
   PubMed Web of Science ®Google Scholar
• Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 2001;3:128–133.
   PubMed Web of Science ®Google Scholar
• Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315–5320.
   PubMed Web of Science ®Google Scholar
• Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580–584.
   PubMed Web of Science ®Google Scholar
• Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003;14:3325–3341.
   PubMed Web of Science ®Google Scholar
• Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007;67:5999–6002.
   PubMed Web of Science ®Google Scholar
• Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000–5005.
   PubMed Web of Science ®Google Scholar
• Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, Saito T, Masuda N, Watanabe H, Taguchi T, Kakihara T, Aoyama Y, Hashimoto Y, Nakagawa K. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009;15:3872–3880.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008;26:5198–5203.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 2008;45:S11–S16.
   PubMed Web of Science ®Google Scholar
• Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087–34090.
   PubMed Web of Science ®Google Scholar
• Hu D, Liu S, Shi L, Li C, Wu L, Fan Z. Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells. J Biol Chem 285:18326–18335.
   PubMed Web of Science ®Google Scholar
• Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007;282:26202–26209.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF, Piris MA. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931–1939.
   PubMed Web of Science ®Google Scholar
• Markovic O, Marisavljevic D, Cemerikic V, Perunicic M, Savic S, Filipovic B, Mihaljevic B. Clinical and Prognostic Significance of Apoptotic Profile in Patients with Newly Diagnosed Nodal Diffuse Large B Cell Lymphoma (Dlbcl). Eur J Haematol 2011; 86:246–255.
   PubMed Web of Science ®Google Scholar
• Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn JY, Fest T. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 2002;16:726–735.
   PubMed Web of Science ®Google Scholar
• Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 2005;55:324–330.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang M, Zou P. Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:2179–2183.
   PubMed Web of Science ®Google Scholar